HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing.
With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow.
The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery.
This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment.
To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards.
François Fournier, CEO of HTL Biotechnology, states: "I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction."
As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France.
About HTL
HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide.
To learn more about HTL Biotechnology: https://htlbiotech.com/
LinkedIn: HTL Biotechnology
X: @HTL_Biotech
Instagram: @htlbiotechnology
Press contact
Nathalie Chevallon - HTL Biotechnologynchevallon@htlbiotech.com
View original content:https://www.prnewswire.com/apac/news-releases/htl-biotechnology-inaugurates-a-new-production-line-dedicated-to-sterile-hyaluronic-acid-302474560.html
SOURCE HTL Biotechnology
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
French defence minister announces drone production in Ukraine
French Defence Minister Sébastien Lecornu has stated that a French car manufacturer, in cooperation with a defence company, will launch drone production in Ukraine. Source: Le Monde; European Pravda Details: French car and defence companies will manufacture drones on Ukrainian territory. Lecornu considers this a "mutually beneficial" partnership with Kyiv. "We are launching an entirely new partnership, under which a major French car company will join forces with a small or medium-sized French defence business to establish production lines in Ukraine for manufacturing drones," he said. He did not specify the type of drones but noted they would be used by the Armed Forces of Ukraine. Lecornu also mentioned that these drones would be available to French armed forces so they "maintain constant tactical and operational training that corresponds to the realities" of the war in Ukraine. He said that Ukraine would provide feedback on the use of these drones in combat conditions. "There is no need to ask French citizens to work on the production line in Ukraine," Lecornu emphasised. He added that Ukrainians are "better than us at developing drones and, most importantly, at forming the doctrine of their application". Background: On 5 June, Ukrainian and French defence ministers discussed possibilities for joint weapons production for the needs of Ukraine's defence forces during a meeting in Brussels. Ukraine and its partner countries decided to establish a mechanism for defence production, according to an agreement reached at the 28th meeting of the Ukraine Defence Contact Group (also known as the Ramstein Format) held on 4 June at NATO headquarters. Support Ukrainska Pravda on Patreon!
Yahoo
an hour ago
- Yahoo
In Musk v Trump, the markets will win
City AM columnist Rainer Zitelmann has been predicting a rift between Musk and Trump ever since the two started working together. Now that this has happened, the French daily newspaper L'Express has spoken to him again. The interview was conducted by Thomas Mahler. 'I never believed that the alliance between Elon Musk and Donald Trump would last,' you told L'Express in April. Why were you so certain that the alliance between the two men would fall apart so quickly? I have read every single biography about these two men and have been following their exploits closely for many years. Trump only tolerates people who completely subordinate themselves to him, whereas Musk won't bow to anyone. And especially not to someone he is so superior to both in terms of intelligence and as an entrepreneur. This is something I have stated on numerous occasions, including in an interview with L'Express in April. On top of that, Trump is not an advocate of economic freedom, his only two convictions are these: he is the greatest and should be all-powerful, and that tariffs are amazing. Trump thinks that tariff is the most beautiful word in the dictionary (which, by the way, is just as absurd as saying that taxes are the most wonderful word in the dictionary). Musk, in contrast, is in many ways a libertarian – he hates high taxes, tariffs, and excessive federal spending that ramp up U.S. debt. Tesla shares fell again after Musk's criticism of Trump's tax bill, and Trump threatened to cut public funding for SpaceX. As an entrepreneur, did Musk lose a lot with his political adventure? That may be the case – but no one can say for sure just yet. I admire Musk, he is driven by deep personal convictions and has consistently taken huge risks throughout his career. So far, those risks have always paid off. Whether Musk will prevail against Trump is debatable, because while Musk is a far superior entrepreneur, Trump outguns Musk in the field of political communication. If Musk were as politically desperate as Trump, he would go to China, which would quickly become the most successful nation in space exploration. If the European Union was not so stupid, it would offer Musk the opportunity to bring SpaceX to Europe on excellent terms. What would be the consequences for the US if they lose SpaceX? Without SpaceX, the US does not currently have much to offer. Prior to SpaceX, they couldn't even transport their own astronauts to the International Space Station and had to rely on outdated Russian rockets – and paid exorbitant prices to do so. In 2024, there were 134 SpaceX launches out of 261 space missions worldwide. If SpaceX were a country, it would easily surpass the second-largest, China, which had 68 launches. Notably, SpaceX is responsible for 86% of all U.S. launches and has delivered more than 80% of the world's total payload weight into orbit and beyond. Incidentally, there were just three launches in Europe. According to you, was Musk right to call Trump's funding bill a 'disgusting abomination'? Absolutely. Not because of the tax cuts – they're the right thing to do! But because Trump has thrown his weight behind a budget that dramatically exacerbates the national debt. Trump's funding bill is a continuation of the insane debt-fueled policies of Obama, Biden, and Trump's first term in office. Consequently, the US is spending more and more on interest payments. Musk must be deeply frustrated: he's neglected his companies for months to help the US government do something it is completely incapable of – namely, reducing the national debt, even just slightly, through the DOGE initiative. And then Trump turns around and backs legislation that does the exact opposite, massively expanding an already astronomical debt mountain. Does this mean that Trump will go even further in his obsessions for protectionism or immigration? Did the MAGA movement and Steve Bannon win the fight inside the Republican camp? It's too early to tell. But if Bannon did come out on top, it would be a disaster for the United States. Musk believes in political and economic freedom. Bannon, at heart, is a right-wing anti-capitalist. Are you worried about the US economy? Absolutely. Trump has promised the American people that his protectionist policies will bring about a new 'Golden Age.' That's complete nonsense. No country has ever become wealthy through protectionism – but many have become poor because of it. A hundred years ago, Argentina was as rich as the U.S., and then, over decades, Peronists drove it into poverty with their protectionist policies. My only hope lies in the capital markets – the stock and bond markets. If anyone can force Trump to change course, it will be the financial markets. I hope the markets prove to be stronger than Trump. Dr Rainer Zitelmann is a German historian, sociologist and author. His latest book is 'The Origins of Poverty and Wealth' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Goldman Sachs Upgrades Bayer (BAYRY) to Buy
On Thursday, Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price target of EUR 33. Quigley indicated that the stock's risk/reward profile appears positive as it approaches H2 2025, with potential catalysts that could drive a re-rating in the medium term. A closeup of pills in a pharmacy, representing the high quality medications of the company. This upgrade follows Bayer's strong operational start to the year, characterized by cost discipline in its Crop Science division and robust momentum in its underlying Pharmaceuticals business. Goldman Sachs suggests that these factors indicate Bayer may have reached the bottom of its negative earnings revision cycle. In key business developments, Bayer's EPS stood at EUR 2.49 in Q1 2025, keeping the company on track to achieve EUR 4.50 to 5.00 at constant currencies for the full year. While sales in the company's Crop Science division declined by 3% due to regulatory impacts affecting higher-margin sales, the Pharmaceuticals segment sales grew by 4% due to an 80% year-over-year increase in Nubeqa and Kerendia sales. Nubeqa is a prostate cancer drug, while Kerendia is used to treat chronic kidney disease associated with type 2 diabetes. The Consumer Health segment sales also increased by 2.5%. Bayer Aktiengesellschaft (OTC:BAYRY) is a global life science company. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. While we acknowledge the potential of BAYRY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Related Content OTC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
